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ABSTRACT 
Human American trypanosomiasis, commonly called Chagas disease, is one of the most 
neglected illnesses in the world and remains one of the most prevalent chronic infectious 
diseases of Latin America with thousands of new cases every year. The only treatments 
available have been introduced five decades ago. They have serious, undesirable side 
effects and disputed benefits in the chronic stage of the disease - a characteristic and 
debilitating cardiomyopathy and/or megavisceras. Several laboratories have therefore 
focused their efforts in finding better drugs. Although recent years have brought new clinical 
trials, these are few and lack diversity in terms of drug mechanism of action, thus resulting in 
a weak drug discovery pipeline. This fragility has been recently exposed by the failure of two 
candidates; posaconazole and E1224, to sterilely cure patients in phase 2 clinical trials. 
Such setbacks highlight the need for continuous, novel and high quality drug discovery and 
development efforts to discover better and safer treatments. In this article we will review past 
and current findings on drug discovery for Trypanosoma cruzi made by academic research 
groups, industry and other research organizations over the last half century. We also 
analyze the current research landscape that is now better placed than ever to deliver 
alternative treatments for Chagas disease in the near future. 
INTRODUCTION 
Chagas disease is named after the Brazilian physician Carlos Chagas who first described the 
disease in 1909 [1]. Chagas disease is caused by the parasite Trypanosoma cruzi and is 
considered to be the parasitic infirmity with the biggest social and economic burden in Latin 
America [2]. There is an estimate of 7-8 million people currently infected with T. cruzi, while 
there are approximately 25 million people at risk of acquiring the disease [3]. Every year, 
Chagas disease claims 10,000 deaths in endemic countries [4]. The parasite has a complex 
life cycle, alternating between the mammalian host and the hematophagous triatomine insect 
vector. The infection begins when the infected bug feeds on the host, which can be a wild or 
domestic mammal or a human. Infective metacyclic trypomastigote forms of T. cruzi are found 
in the feces of the bug which are released during the blood meal, and gain access through the 
lesion to infect dendritic cells [5]. Once inside a cell, the parasite breaks free of its entering 
organelle, the endosome/lysosome, and differentiates into a replicative amastigote form. The 
amastigote divides several times and maturates in to bloodstream trypomastigotes that 
rupture the host cell and are released in to the bloodstream or lymph, free to infect a wide 
range of cells or be ingested by the transmitting vector, thus closing the cycle. In the 
triatomine gut, the parasite transforms once again in to a replicative stage called the 
epimastigote and after clonal divisions it migrates to the final portion of the intestine and 
differentiates again in to infectious metacyclic trypomastigote.  
Although vectorial transmission has been greatly reduced due to vector control campaigns 
carried out by the World Health Organization (WHO), the Pan-American Health Organization 
(PAHO) and national health ministries of participating countries, there are still about 41,000 [6] 
new cases each year due to vectorial transmission. Many thousands of cases can be also 
attributed to secondary infection routes like transfusion of contaminated whole blood and 
derivate products, transplant of organs from chronically infected patients, congenital and oral 
transmissions. Oral transmission is a growing concern, with 138 outbreaks responsible for the 
appearance of 776 new cases in the period of 2000–2010. Oral infection is usually acquired 
through ingestion of food, sugar cane and other juices, water or soup contaminated with 
infected triatomines or their feces [7]. Moreover, human migration in recent years has 
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increased the incidence of new cases in non-endemic countries, making Chagas disease a 
public health issue in North America, Europe, Japan and Australia, requiring governments to 
implement screenings for blood and organs donations, as well as implement infrastructures to 
treat infected patients [8].  
Due to the huge vertebrate reservoir and the variety of triatomine insects, the eradication of 
this zoonotic parasite is practically impossible [9].  
The symptomatology of Chagas disease may vary according to the route of infection: while 
vectorial transmission is usually asymptomatic or presents non-specific symptoms, oral 
infection may increase the chance of acute cardiomyopathy because of the higher parasite 
loads associated. About 20 to 30% of acute cases develop serious chagasic cardiomyopathy 
with evolving symptoms and the risk of sudden death [10]. Fifteen to 20% develop digestive 
tract manifestations. The remaining infected individuals are considered to have the 
indeterminate form of the disease and the majority may not have symptoms or signs of the 
disease for all their life [10].  
To treat new acute cases, indeterminate phase patients or reactivations from chronic patients, 
the only drugs available were introduced more than four decades ago, with no alternatives. 
Benznidazole and nifurtimox (Fig. 1A& B) are effective in treating acute infections, but efficacy 
is thought to decrease with the disease progression, with little to no effect in the chronic 
phase. Additionally, they must be administrated for long periods of time and display numerous 
side effects. Some of the most serious side effects require monitoring and ultimately, 
treatment interruption. 
For the above reasons, new drugs to fight this disease are a dire need. New formulations of 
old drugs, old drugs with new applications as well as innovative drugs are feeding the pipeline 
for the treatment of Chagas disease [11]. In the following sections we will discuss the 
therapies available today and their limitations followed by the advances in the drug discovery 
and the candidates currently in preclinical and clinical studies to treat Chagas disease. 
CURRENT THERAPIES 
Benznidazole. Benznidazole (Fig. 1A) is a nitroimidazole (N-benzyl-2-(2-nitro-1H-imidazol-1-
yl)acetamide) discovered in 1972 at Roche Laboratories, and originally marketed as 
Rochagan
TM
 or Rodanil
TM
. Despite being introduced several decades ago, it is still the frontline 
treatment for the disease, although it is not approved by FDA [12]. Benznidazole is considered 
to be effective in reducing symptom severity and to shorten the clinical course and the 
duration of detectable parasitemia. Clinical cures are thought to be achieved in 60 to 85% of 
the acute cases and in more than 90% of congenitally infected infants, if treated in their first 
year of life [13]. Efficacy of benznidazole in chronic Chagas diease is still debatable, with 
reports varying from 15-35% of cure rates [14, 15]. The benefits of the drug in preventing 
cardiac and/or megacolon and megaesophagus manifestations were not clear for a long time 
[16]. To address this uncertainty, a large, multicenter, double-blind, randomized, placebo-
controlled clinical trial called BENEFIT (The Benznidazole Evaluation For Interrupting 
Trypanosomiasis, Clinical Trials.gov, ID: NCT00123916) with 3,000 patients in several 
endemic countries has recently been concluded and demonstrated that a daily dose during 40 
to 80 days of treatment failed in reducing mortality and morbidity in patients with chronic 
Chagas cardiomyopathy [17]. Problems with precise dosing in young children and the adverse 
effects observed has led to the development of a new pediatric formulation of benznidazole. 
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This lower dose, easily dispersible tablet that should improve dosing accuracy, safety, and 
adherence to treatment is currently in clinical trials (Population Pharmacokinetics Study of 
Benznidazole in Children With Chagas' Disease -Pop PK Chagas, ClinicalTrials.gov, 
ID:NCT01549236). A previous clinical trial by the same team already validated the use of a 
lower dose benznidazole regimen for children aged 2 to 12 years old (Population 
Pharmacokinetics of Benznidazole in Children With Chagas Disease, ClinicalTrials.gov, 
ID:NCT00699387) [18]. Recently, a study on the pharmacokinetics of a new formulation of 
benznidazole (Abarax®, Elea Laboratories) in adults with Chagas disease also suggested that 
a dose reduction may be feasible [19].  
The mechanism of action of benznidazole is thought to require the reduction of its nitro group 
by a trypanosomal NADH-dependent type I nitroreductase with generation of cytotoxic 
products that lead to thiol depletion and that can readily form adducts with many biological 
macromolecules like proteins, lipids and DNA that disrupt normal cell function and metabolism 
[20]. It is also thought that T. cruzi NADH-fumarate reductase inhibition, phagocytosis 
improvement and death by INF-γ are additional mechanisms involved in parasite killing by 
benznidazole [21]. On the other hand, reduction by human liver NADPH, cytochrome P-450 
reductase, P450, xanthine oxidase and aldehyde oxidase are thought to be responsible by the 
adverse side effects in patients [22]. 
While treatment with benznidazole is usually well tolerated by infants and children [23], adults 
frequently report adverse effects [24]. The most common side effect is dermatitis from 
hypersensitivity to the drug, appearing in up to 50% of the patients, usually after 10 days on 
the treatment, and for this reason, onwards weekly monitoring is recommended [25]. Digestive 
intolerance, peripheral neuropathy, depression of bone marrow, toxic hepatitis and 
lymphomas are other occurring side effects. Treatment interruption is most frequently due to 
dermatitis and digestive intolerance, although studies reveal that low-fat and hypoallergenic 
diet and daily dose administrations can reduce their incidence [25]. In addition, benznidazole 
should not be administered to pregnant women nor patients with severe renal or hepatic 
dysfunction, because of drug metabolization by these organs [26]. Exposure to the drug 
through breastfeeding is thought to be limited and unlikely to pose a risk [27].  
Resistance to benznidazole has been reported under experimental conditions, however it is 
not yet clear how drug resistance correlates with benznidazole therapeutic failure in chagasic 
patients. An example is the Colombian strain, with benznidazole only being able to cure up to 
16% of the mice infected with different clones [ 
28]. In vitro results using real-time PCR suggest nitroreductases (NTRs) as the main 
mechanism of resistance in vitro, probably due to loss of a NTR gene copy [29]. A recent 
study warns of the relative ease in which benznidazole can develop resistance in vitro by a 
couple of different mechanisms such as chromosome loss and different point mutations in the 
NTR gene, all arising from a single population [30]. 
Nifurtimox. Nifurtimox ((R,S)-3-methyl-N-[(1E)-(5-nitro-2-furyl)methylene]thiomorpholin-4-
amine-1,1-dioxide) a 5-nitrofuran derivative (Fig. 1B), constitutes the second and only 
alternative to benznidazole for the treatment of Chagas disease. Like benznidazole, the FDA 
has not yet approved chemotherapy of Chagas disease with nifurtimox. Also known as Bayer 
2502, the drug, marketed as Lampit
TM
, was originally discovered in that pharmaceutical 
company in 1965, exactly 50 years ago and provided, for the first time, a treatment for 
chagasic patients. It is also used in combination therapy with eflornithine to treat second stage 
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Human African trypanosomiasis caused by the parasite Trypanosoma brucei gambiense [31, 
32]. 
Nifurtimox efficacy is similar to benznidazole, but it has a much higher frequency of adverse 
effects [13, 26]. There is a frequency of adverse effects in 98% of patients, with only 56% of 
them completing the 60-day course treatment and 29% not tolerating it for more than 30 days. 
Digestive symptoms are predominant and neurological alterations the most persistent. An 
estimated 7% of patients had severe adverse effects like angioedema, myocarditis and grade-
3 anaphylactic reactions [33]. 
Recently, a study highlighted the possible biochemical mechanisms that may be associated 
with some of nifurtimox adverse side effects and as well as from other nitro-aromatic derived 
drugs [34].  
Nifurtimox acts through a mechanism of intracellular nitro-reduction with the generation of the 
nitro radical, followed by redox cycling. In contrast, there is a greater role for oxygen reactive 
species, like superoxide ion and hydrogen peroxide which are toxic to T. cruzi. This parasite is 
sensitive to oxidative stress due to weak detoxification mechanisms due to the absence of 
catalase or peroxidase activity and reduced superoxide dismutase activity [21, 35]. RNA 
interference studies on Trypanosoma brucei show that besides NTR, other proteins linked to 
ubiquinone synthesis are also involved in nifurtimox mechanism of action in that species, and 
it is likely that the same mechanism is also present in T. cruzi [36]. 
Resistance to nifurtimox is readily obtainable in vitro and it seems parasite nitroreductases 
play a major role in its resistance, mounting up evidence that cross-resistance with 
benznidazole can occur as has been reported [37, 38], increasing the pressure to find 
alternative drugs to treat patients refractive to the only available therapies. 
DRUG DISCOVERY AND DEVELOPMENT FOR CHAGAS 
DISEASE 
Drug Discovery Strategies. Various approaches can be adopted when considering the 
development of new drugs, and the field of neglected tropical diseases in particular has 
employed distinct strategies in the search [39]: (i) “De novo synthesis” is a classical way that 
focuses on the identification of new chemical entities through target discovery and compound 
screening. Although this is an important strategy to consider in the discovery of novel drugs 
for neglected diseases, it is a long-term approach. There are constrains like a high attrition 
rate of candidate compounds and the need for significant human and financial resources. 
Because of those issues and the perspectives of low market return and profits, the majority of 
companies do not make neglected tropical diseases a priority [40]. Populations affected by 
neglected diseases, and Chagas disease in particularly, are economically poor and don’t have 
the means to pay for expensive medication [41]. (ii) “Piggy-back” discovery is the name given 
to a process that takes advantage of prior research for an unrelated disease. It uses the data 
and chemical start points previously generated for a molecular target also present in the 
organism of interest. An example is the use of kinase inhibitor research data from cancer 
treatment to provide shortcuts for the development of a kinase inhibitor against a parasitic 
target. (iii) Label extension or drug repurposing is the approach with the most immediate 
results, in that it uses already approved drugs for some pathologies, and re-purposes them to 
be used in neglected diseases, saving considerable time and costs for approval processes 
after efficacy confirmation. Most of the toxicological data and often clinical tests are already 
 Version: Postprint (identical content as published paper) This is a self-archived document from i3S – Instituto de 
Investigação e Inovação em Saúde in the University of Porto Open Repository For Open Access to more of our 
publications, please visit http://repositorio-aberto.up.pt/  
 
A
0
1
/0
0
 
available. An example of successful application of this strategy is the case of praziquantel for 
schistosomiasis and ivermectin for filariasis/onchcocersiasis [39, 42]. More recently, 
auranofin, an approved drug for rheumatoid arthritis, has been identified as an amebacide [43] 
and a clinical trial is being launched in Bangladesh. So far, no drug has been repurposed for 
Chagas disease but some studies are devoted to find an extension for existing drugs 
employing both in vitro and in silico screening strategies [44, 45]. 
Independent of the strategy used, an essential feature of the drug discovery process that 
plays a guiding role is the target product profile (TPP). TPPs are a set of criteria to be followed 
through the development process and describe the needs and characteristic that the new 
candidate has to meet in order to constitute an improvement over the current available 
therapies. Drugs for Neglected Diseases initiative (DNDi), a non-profit drug research and 
development organization founded with the objective to develop therapies for neglected 
diseases, has recently updated a TPP for Chagas disease [46]. 
Starting Points: Screening for Hits. Two different approaches can be taken to identify 
starting points for drug discovery: a molecular target or target-based approach, and a 
phenotypic approach, also known as untargeted drug discovery. Target-based drug discovery 
relies on the previous discovery and characterization of a given molecular target and 
subsequent target validation by chemical or genetic means. Each has advantages 
anddisadvantages [47]. Ideally, a target should be validated by more than one method. 
Chemical and biochemical validation is the proof that a molecular target, usually a protein, is 
able to be inhibited by a small molecule and that the use of such molecule in the parasite 
and/or in vitro and in vivo models of the disease leads to deficient parasite grow or ability to 
establish a normal infection. Genetic validation implies the reduction or elimination of the 
molecular target at the cellular level and the consequent observation of the interference in the 
parasite fitness/survival. The only reliable way to genetically validate a protein target in T. 
cruzi is by gene-knockout. Because of the low recombination potential of the parasite and 
slow growth kinetics, these transgenic techniques are extremely hard and time consuming to 
perform, with high failure rates and many weeks just to select stable transfected cells [48]. 
Unfortunately and unlike the related species Trypanosoma brucei, T. cruzi does not have 
functional RNAi machinery. Apparently some of its components have been lost or mutated 
during evolution [49, 50]. Most recently, CRISPR-Cas9 technology has been successfully 
applied to T. cruzi with major breakthroughs like reduction of gene expression of an enzyme 
gene family consisting of 65 members [51]. Chemical validation of a target requires a very 
specific and selective inhibitor or probe for a given target. Both genetic and chemical 
approaches therefore have limitations.  
After drug target validation, biochemical assays can be set up to screen for inhibitors. These 
assays usually make use of proteins, frequently of recombinant origin. In the past, many of the 
labs working with T. cruzi have screened only a small number of compounds, from either 
synthetic or natural origin. The scenario changed dramatically with the development of high 
throughput technology based on assay miniaturization and automation of protocols, from 
procedure to analysis. This opened the door to large scale screening campaigns for targeting 
T. cruzi. Among the advantages brought by these innovations are the reduction of time to 
screen libraries, assay cost reduction and data reproducibility. As an example, one high-
throughput screen of 200 000 compounds against cruzipain, yielded 921 hit compounds that 
were subsequently screened by computational docking analysis to reveal 5 chemical scaffolds 
of common hits. These scaffolds are good starting points for further optimization and 
evidentiate the advantages of combining biological and bioinformatics analysis for priorization 
of molecules after an high-throughput screening campaign has been performed [52]. In 
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another example of target-based drug discovery, CYP51 from Mycobacterium tuberculosis 
was screened against a library of 20 000 organic compounds and resulted in two very active 
compounds [53], of which one (ChemDiv C155-0123) later showed selective inhibitory activity 
against the T. cruzi orthologous enzyme [54]. 
The limitations of molecular target approaches are the possibility of poor translation to a 
therapeutic effect, low druggability of the target, risk of off-target effects and the chance of 
redundant research by different groups since there are so few targets characterized [55]. 
To circumvent such limitations, phenotypic approaches have been developed. Instead of a 
single molecular target, whole cells are tested directly with the compounds and selection is 
made based on the observance of the required phenotype. This allows the selection of only 
those compounds that are active against the parasite, despite their mechanism of action. Also, 
it readily selects those compounds with the minimal pharmacodynamic and pharmacokinetic 
properties needed: proper intracellular distribution and accumulation, physiological binding 
and inhibition to target, etc., that are very difficult to predict with target-based strategies. 
However, this method requires that the target must be elucidated in the discovery process, a 
task not always easy but achievable [56]. The most recent trend in whole-cell assays has 
employed the use of high-content screening analyzers – automated microscopes that can 
image many conditions (compounds) in clear bottom culture microplates. When the 
technology appeared one assay was developed that made use of mammalian cells expressing 
GFP and parasites stained with DAPI, and both manual and automated data analysis was 
performed [57]. Because of limitations of genetically modified parasites/host cells, 
anotherscreening technology was developed that used unmodified cells and parasites. This 
assay was validated with a small library of FDA-approved drugs [44]. The development of 
analysis software further automates the campaigns and allows the additional mining of 
important data, for example, the toxicity for host cells [58]. The first multi-thousand screening 
campaign described in the literature has been recently published [59]. 
Balancing the benefits and disadvantages of both strategies in hit identification for parasitic 
diseases such as Chagas, phenotypic approaches emerged as the most promising 
methodologies [39]. Hits are selected for their ability to kill or not the parasite, coupled with 
cytotoxicity evaluation. When recent first-in-class new drugs, with innovative molecular 
mechanisms of action are tabulated, many of these were discovered by phenotypic screening 
(28 versus 17) [60]. 
From Hit to Lead and Beyond. Once single point hits have been obtained, the most 
promising are further validated in a dose-response-curve to confirm activity. Most guidelines 
suggest an EC50 lower than 10 μM as a good starting value, although recommendations can 
vary if other criteria are met, like a high selectivity index, for instance. The confirmed hits can 
also be subject to complementary activity assays. These can be of a different configuration, 
employ a different readout, or even assess activity against other strains. A recent paper 
shows that a set of compounds in clinical trials have significantly different activity profiles 
depending on the strain they are tested on [61]. As has been discussed above, it is a requisite 
of the TPP for Chagas disease that a future drug is active against a large set of different 
DTUs. Another key unanswered question is whether a compound must clear the infection 
totally, as the reference compound, benznidazole, does. Does total clearance of infected cells, 
or parasites in animals or humans correlate with multi-strain activity or, more importantly, with 
the clinical course of disease in the subsequent 20 years? Compounds that still meet agreed 
upon pharmacological and biological properties are called lead compounds. Leads are at the 
end of the screening campaign, but are the starting points of yet another phase in the drug 
 Version: Postprint (identical content as published paper) This is a self-archived document from i3S – Instituto de 
Investigação e Inovação em Saúde in the University of Porto Open Repository For Open Access to more of our 
publications, please visit http://repositorio-aberto.up.pt/  
 
A
0
1
/0
0
 
discovery and development called lead optimization. In this phase, compounds enter a cycle 
of further testing, commonly with in vivo testing of activity, PK/PD, and toxicity. Leads are 
optimized by a medicinal chemist to try to improve potency, selectivity, reduce toxicity and 
enhance pharmacokinetic parameters [40]. The medicinal chemistrynecessary for lead 
optimization is very costly and constitutes a bottleneck for many drug discovery efforts. Few in 
academia have the resources or access to the synthetic chemistry capacity necessary to 
produce the tens to hundreds of compounds usually required for lead optimization. 
Organizations such as DNDi and recently launched consortia-based projects like the FP7 
(Seventh Framework Program supported by the European Commission) KINDReD 
(Kinetoplastid Drug Development), NMTrypI (New Medicines for Trypanosomatidic Infections), 
PDE4NPD (Phosphodiesterase Inhibitors for Neglected Parasitic Disease) and A-PARADISE 
(Anti-Parasitic Drug Discovery in Epigenetics) have attempted to address this issue by 
coordination or outsourcing. 
The optimized lead compound is one which can be called a pre-clinical candidate and enter 
the pre-clinical phase. 
Animal Models. Animal models are used to extract the maximum possible information on 
drug efficacy and toxicity before testing the drug candidates in humans. Since the translation 
of data is of the utmost importance, several animal models have been studied to reproduce 
the physiopathology of Chagas disease. Models including mice, rats, rabbits, dogs and non-
human primates have been tried, but none of them completely mimics what happens in the 
human host [62]. The rat has been used in the past, but early observations concluded that it is 
somewhat resistant to T. cruzi infection, developing a mild and slow pathology [63]. Rabbits 
develop some of the chronic alterations such as focal myocarditis with a fibrous component, 
but do not show more severe forms of chronic myocarditis or the histological lesions in 
digestive track and skeletal muscles found in typical infections [64]. The Syrian hamster has 
also been proposed as an animal model for chronic Chagas cardiomyopathy but it was not 
able to reproduce all the characteristics findings of human cases [65]. Dogs, on the other 
hand, develop most of the clinical aspects of the disease found in humans. This includes 
modeling of the indeterminate stage of disease characterized by a latent infection without 
disease signs or symptoms and with normal electrocardiograms. Just a fraction of these 
animals develop chronic phase signs and symptoms [66, 67]. Monkeys are the closest 
phylogenetically related species to be used to study Chagas disease and results are more 
easily extrapolated to humans [67, 68]. 
Nevertheless, the mouse has remained the preferred animal model. Mice are easy to handle, 
house and are cheaper. Additionally, mouse models resemble many immunological, 
pathological and physiological aspects of human Chagas disease. One of the strains 
commonly used in experimental chemotherapy is Swiss mice, an outbred strain very sensitive 
to diverse T. cruzi genotypes [69]. Regarding inbred strains, Balb/C has also been extensively 
used and is considered one of the most susceptible to parasite infection in general [70]. C3H 
are a mildly resistant mouse strain commonly used to obtain chronic-like infection in these 
animals [71]. C57BL/6 are considered to be among the most resistant strains, although 
susceptibility can vary  
Widely depending on the strain of trypanosome used [72]. This genetic background is 
frequently used to obtain chronically infected mice in attempts to reproduce the 
pathophysiology of the chronic human disease. 
Chronically infected mouse models develop an anti-inflammatory infiltrate and fibrosis in the 
heart, hallmarks of the disease in humans, but still lack extensive fibrosis, segmental 
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myocardial abnormalities and macroscopic ventricle dilatation that closely resemble human 
chronic cases Chagas cardiomyopathy [65]. According to current protocols, four strategies 
have been employed to try to mimic chronic Chagas disease in mice: (a) a combination of 
susceptible mice strain, pathogenic T. cruzi DTU, age of animals and inoculation route that 
guarantees the survival of the animals to the acute phase; (b) infection of mice with a lethal 
dose of T. cruzi followed by the treatment with a reference drug that assures animal survival, 
but not parasite clearance; (c) infection of resistant strains of mice with sub lethal inoculum of 
low pathogenic DTU; (d) infection of animals immunized by attenuated strains with a 
pathogenic DTU [73]. 
There are also dozens of different T. cruzi strains that have been used in animal models of the 
disease. Each research group works with a limited set of biological specimens that may reflect 
the history of the lab. An illustrative example of this variability is the case of A/J and 
C3H/HePAS mice infected with the same clone of Sylvio X10/4. Distinct histopathological 
findings are reported, suggesting a host genetic role in the manifestations and progress of the 
disease [74]. This variability hinders the extrapolation of results to other animal models and, 
ultimately, to humans. 
Recent guidelines for in vivo testing of compounds in Chagas disease drug discovery have 
been elaborated. One protocol suggests three independent and consecutive in vivo 
evaluations of drug candidates: (1) testing for the effect of the compound on parasitemia 
reduction using Swiss female mice infected with Y strain, three doses of compound with the 
highest one set at the maximum tolerated dose, orally or intraperitonially, and after five days 
of infection for a duration of five consecutive days; (2) analysis of parasitological cure during 
the acute phase using Swiss female mice infected with Y strain, with the dose established in 
the previous stage; (3) cure the acute phase of parasitemia caused by Colombian strain, 
which is benznidazole resistant [75]. Parasitemia is analyzed at 5, 8 and 10 days post 
infection (dpi) for (1) and (2) and at 20, 25 and 30 dpi for (3). Mortality is evaluated for all the 
three phases at 30 days and PCR, after immunosuppression with cyclophosphamide, to 
detect “latent” parasites. This technique was employed because it was proved to be more 
sensitive and time-efficient than haemoculture. All the tests are done against a positive control 
of 100 mg benznidazole per kilogram of weight per day [75]. The effectiveness in the chronic 
and indeterminate stage takes place later in the development process, and the lack of it does 
not invalidate the prospective drug since, if the TPP is followed, it should be already an 
advance over existing therapies. 
Biomarkers. Another obstacle in the drug discovery for Chagas disease has been the lack of 
reliable biomarkers of cure. Traditionally, the definitive test of cure relies on conventional 
serology methods that have the limitation that it can take many years for the seroconversion to 
take place. Also, the majority of currently used methods employ crude antigen preparations 
from parasite life-cycle stages not present in the mammalian host. Polymerase chain reaction 
is the standard method of cure in the current clinical trials and although useful, there is no 
proof of efficacy and it is only an indication of sterile cure for a given therapy [76]. Newer tests 
using recombinant proteins or peptides may be anim provement, but results are often 
inconsistent [77]. A recent and promising discovery in the field has been the identification of 
unusual fragments of human apolipoprotein A1 (APOA1) that are specifically present in 
chagasic patients and seem to disappear after treatment with nifurtimox [78, 79]. In mouse 
models, different methodologies to access parasitological cures were used after treatment 
with benznidazole and found out that even mice considered cured by hematological criteria 
still showed positive PCR tissues, either indicating a residual infection or presence of 
remaining parasite DNA [80]. 
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TARGET CANDIDATES IN THE PIPELINE 
Ergosterol Biosynthesis Inhibitors. Inhibitors of sterol 14α-demethylase (CYP51) constitute 
a major fraction of all the drugs in the Chagas disease pipeline [11]. This enzyme is involved 
in the de novo synthesis of sterols in T. cruzi. While in mammals the major sterol is 
cholesterol, in plants, fungi and protozoa the major sterol present is ergosterol. The difference 
consists of a second double bond at the B ring and a fully saturated side chain with a methyl 
group at C24 in cholesterol [81]. CYP51 catalyzes a critical step of this biosynthetic pathway, 
removing the C14 methyl group from the sterol intermediate eburicol and originating 14α-
demethyl-14dihydroeburicol [82]. 
Ergosterol biosynthesis inhibitors are among the most common drugs used to treat fungal 
infections, and after the validation of this pathway in T. cruzi, compounds that were originally 
developed as antifungals were tested against the parasite. While some of the early generation 
imidazoles (e.g. miconazole, ketoconazole) and triazole (e.g. itraconazole, fluconazole) sterol 
biosynthesis inhibitors have some attenuating effect on the infection, they failed in achieving 
parasitological cures [83]. However, as newer azoles to treat fungi infections are still an 
ongoing interest for pharmaceutical companies, later generation drugs have also been tested 
for anti- T. cruzi activity. 
One of the most promising molecules of the past decade was posaconazole (Fig. 2A). This 
triazole originally marketed as Noxafil by Schering-Plough pharmaceutical and active against 
Candida spp. and Aspergilus spp. is one example of the previously described drug 
repurposing strategy. Early assays demonstrated its potent and specific in vitro activity against 
T. cruzi, especially against the amastigote stage. Moreover, the effect on murine acute and 
chronic models was curative, rather than suppressive, as some earlier tested antifungal 
compounds demonstrated [84]. Later, posaconazole also proved to be an efficient 
trypanocidal against benznidazole and nifurtimox resistant strains, even in immunosuppressed 
mouse models, where the parasite would have a favorable environment to multiply [85]. A 
comparative study between posaconazole and benznidazole in a mouse model of Chagas 
disease showed both drugs led to 100% survival rates, suppression of parasitemia and 
negative T. cruzi antibodies. Only posaconazole-treated mice had completely negative 
haemocultures 54 dpi, whilst 50% of the benznidazole-treated had positive results. Also, 
plasma enzymatic assessment of cardiac lesion was indistinguishable from uninfected control 
for posaconazole, but significantly higher for benznidazole [86]. These promising results led to 
two clinical trials: one phase 2 trial  sponsored by Hospital Universitari Vall d'Hebron Research 
Institute (ClinicalTrials.gov, ID: NCT00349271, CHAGASOL) that evaluated posaconazole and 
benznidazole for the treatment of Chagas disease chronic infection [87] and a phase 2 trial by 
Schering-Plough (now merged with Merck & Co.) for the treatment of asymptomatic Chagas 
disease, comparing a posaconazole with a placebo regimen and a combination of 
posaconazole with benznidazole (ClinicalTrials.gov, ID: NCT01377480, STOPCHAGAS) [88]. 
When evaluating posaconazole in patients, it is noteworthy that a woman with chronic Chagas 
disease and systemic lupus erythematous requiring immunosuppression, was treated with 
posaconazole eliminating T. cruzi completely, whereas benznidazole treatment failed in this 
patient [89]. 
Unfortunately, the first clinical trial of posaconazole in humans did not replicate the results 
reported for the first patient. The treatment, consisting of two doses delivered orally for 60 
days, had initial marked antitrypanosomal activity in chronic Chagas disease affected patients, 
but followup at the end of treatment suggested reactivation of infection, as documented by 
PCR. All but one patient treated with benznidazole showed negative PCR. The second clinical 
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trial has finished in January 2015 and the final results should be published soon thereafter. 
Moreover, two recent studies have demonstrated that benznidazole has a curative activity 
superior to that of posaconazole in newly developed mice models, suggesting that activity 
observed for a drug is highly dependent on the model used [90, 91]. 
Another ergosterol biosynthesis inhibitor in the recent pipeline was E1224 (Fig. 2B) from Eisai 
Co. E1224 is the monolysine salt of ravuconazole, thus a pro-drug of an antifungal with a 
short half-life. In this trial, which began in Bolivia in July 2011 as a partnership of DNDi and 
Eisai, adults with chronic “intermediate” Chagas disease were given placebo, E1124 or 
benznidazole (ClinicalTrials.gov, ID: NCT01489228). A series of examinations were then 
carried out in the following months in order to evaluate parasitological cures [92]. According to 
DNDi, the drug failed to maintain sustained efficacy 1 year after the end of treatment. The 
advantage of E1224, was that the structure of this compound was simpler and thus synthesis 
should be less expensive. 
A third ergosterol biosynthesis inhibitor in clinical trials is Tak187 (Fig. 2C), a triazole 
synthetized in the 1990’s and the property of Japanese Takeda Chemical Industries. There 
was 100% survival in the acute model of Chagas disease in mice treated with Tak-187 as well 
as a high parasitological cure (80%). In the chronic model, not all mice survived, but in those 
that did there was 100% parasitological cure even with benznidazole and nifurtimox resistant 
T. cruzi strains [93]. Subsequent studies confirmed that the drug could produce reductions of 
parasitemia similar to benznidazole, but at 10 times less dosage. Furthermore, it was superior 
to benznidazole in reducing inflammatory infiltrates and tissue damage in the heart and 
skeletal muscle of infected mice. The superior efficacy was attributable to higher intrinsic 
activity and long terminal half-life [94]. Tak-187 has completed phase I trials [11]. 
The fungicide fenarimol, another inhibitor of CYP51, has been found to affect T. cruzi growth. 
After synthesis of analogues, the most promising compounds were tested in vivo in a Swiss 
mouse model with three dosing regimens. One analogue was effective in the 20 days 
regimen, reducing parasitemia to negligible levels that only reactivated after three cycles of 
immunosuppression [95]. While remaining controversial as to long term clinical effects, the 
failure of repurposed antifungals in Chagas disease clinical trials has focused attention to drug 
leads targeting the T. cruzi CYP51 (TcCYP51) itself [96, 97]. TcCYP51 is one of the most 
studied enzymes of T. cruzi as represented by crystallographic data for 18 structures of the 
protein with 16 different ligands in the protein databank (ww.rcsb.org). Three structural 
features make this protein particularly interesting for a rational drug design approach: (i) high 
structure rigidity, particularly in its substrate binding cavity; (ii) a substrate access channel in 
both ligand-free and bound structures that remains open and well defined; (iii) a substrate 
binding cavity that extends deeper inside the molecule than in other CYP structures [98]. Fig. 
(3) depicts the key structural regions of TcCYP51: the active site residues within the BC 
region (residues 100-120, PDB ID: 3KSW sequence numbering) that close the active site and 
isolate the substrate from solvent; the substrate tunnel through which substrate and ligands 
enter the active site; and the deeper substrate regions occupied by smaller ligands such as 
VNF and LFT (Fig. 4A&B) [97, 99, 100]. Some novel compounds designed to target TcCYP51 
possess a nitrogen atom as a warhead, included in an azole or pyridine heterocycle that are 
able to form a coordination bond with the CYP51 catalytic heme iron and are represented in 
Fig. (4A-C). These compounds are simple and easy to synthetize and demonstrated strong 
inhibitory potential of intracellular amastigote growth of T. cruzi [97, 101-103]. VNI, in 
particular, was able to cure infected mice, has oral bioavailability and low toxicity, making it an 
excellent drug candidate [101]. 
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Other enzymes of the ergosterol biosynthesis pathway may be targeted as potential drug 
targets for Chagas disease, including squalene synthase. This enzyme is responsible for the 
first step of ergosterol biosynthesis and was suggested as target in the parasites Leishmania 
mexicana and T. cruzi [104]. The effective and potent squalene synthase inhibitor 4-
phenoxyphenoxyethyl thiocyanate effective against epimastigote proliferation producing an 
accumulation of mevalonate pathway intermediates is an example of compound targeting this 
enzyme [105, 106]. E5700, a drug from the Eisai Co. which is in development as human 
cholesterol lowering agent, is efficacious against T. cruzi [107]. Amiodarone (Fig. 2E) also 
inhibits ergosterol biosynthesis and is currently in clinical trials (as well as dronedarone) 
against the chronic phase of the disease [11]. This antiarrhythmic drug is used in the 
treatment of cardiac failure in chronic chagasic patients and has been found to act on a 
synergistic manner with azoles in disrupting T. cruzi biology. Amiodarone interferes with the 
calcium hemostasis but also inhibits ergosterol biosynthesis, while posaconazole or 
itraconazole also affects calcium hemostasis, suggesting a viable and advantageous drug 
combination [108-110]. Allylamine terbinafine, a squalene epoxidase inhibitor, and mevinolin 
inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are antiproliferative against T. cruzi 
and both have been shown to be synergistic with ketoconazole against cultures of the parasite 
[111], suggesting they could be used in the treatment of human Chagas disease [112]. 
Cruzipain Inhibitors. K-777, a vinyl sulfone cysteine protease inhibitor was originally 
synthesized at Khepri Pharmaceuticals as an anti-inflamatory lead (Fig. 2D). It is an 
irreversible inhibitor of cruzipain, also known as cruzain or gp51/57. Cruzipain is a cathepsin 
L-like cysteine protease respon sible for the majority of proteolytic activity in all the stages of 
T. cruzi. It may be essential for metabolism, metacyclogenesis, immune evasion, and invasion 
of host cells [113-116]. It has been suggested not only as a drug target but also as a vaccine 
target. 
Early experiments with mouse models of Chagas disease showed that cysteine protease 
inhibitors were able to rescue mice from lethal infection, displaying repetitive negative 
haemocultures and so indicating parasitological cure [117]. K-777 was able to rescue mice 
from an acute and lethal T. cruzi infection even with a non-functional immune system, as seen 
in immunocompromised patients (e.g. HIV/AIDS) or immunosuppressed individuals (e.g. 
transplantation patients) [118]. K-777 also abrogated myocardial damage in beagle dogs 
treated orally for seven days [119]. 
Several other classes of inhibitors of cruzipain have been reported as potential drug leads, 
including selenosemicarbazones [120], amidines bearing benzofuroxan or benzimidazole 
[121], and other scaffolds [122, 123]. Effective nitrile inhibitors of cruzipain have also been 
identified and serve to chemically validate this target [124]. 
A variety of approaches has been considered to rationally design inhibitors for cruzipain. Most 
of the compounds synthesized were originally designed to target the catalytic cysteine (Cys) 
of another member of the same enzyme family. The protein databank reports 24 
crystallographic structures of cruzipain in complexes with inhibitors. They show that cruzipain 
is composed of one polypeptide chain folded into two domains: one mainly α-helix and the 
other with an extended antiparallel β-sheet. The catalytic triad is Cysteine25, Histidine162 and 
Asparagine182. Together with the extended substrate-binding site, they are found in the cleft 
between the two domains [125]. Within the substrate binding site, different regions (S1’, S1, 
S2 and S3), each devoted to the interaction with and binding of a residues of the peptidic 
substrate, have been recognized (Fig. 5) [126]. The S2 pocket, which has Glutamic acid 208 
at the base is the key determinant for substrate specificity. This region adopts a substrate-
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directed conformation if the S2 site is occupied by a basic or uncharged hydrogen bonding 
residues (such as Arginine and Tyrosine, respectively) whereas it assumes a solvent-directed 
conformation when an hydrophobic residue (such as Phenylalanine) is bound [127]. Scaffolds 
designed to inhibit cruzipain include acylhydrazones, thiosemicarbazones and methoxyphenyl 
ketone derivatives. The discovery of acylhydrazone compounds as antiparasitic Cys protease 
inhibitors originated from an high throughput screening against brucipain, the related Cys 
protease of T. brucei [128]. Optimized scaffolds of this class of compounds have since been 
synthesized and also inhibited cruzipain (Fig. 4D) [129, 130]. Interestingly, acylhydrazones 
share some similarity with chalchones, in which the unsaturated arylketone subunit can act as 
a Michael acceptor (Fig. 6). Chalchones possess anti T. cruzi activity, but there was no direct 
evidence of cruzipain inhibition [131, 132]. 
A peptide vinyl sulfone (Michael acceptor) cruzipain inhibitor was able to cure parasitic 
infections in animal models, but with low oral bioavailability. An optimized compound derived 
from a methoxyphenyl ketone scaffold and with desirable physicochemical properties has 
been reported (Fig. 4E). Its mechanism of action, supported by the crystal structure of the 
complex, is depicted in (Fig. 7) [133]. Thiosemicarbazones (Fig. 4F) are another class of 
covalent inhibitors that originated from a screening of compounds able to inhibit cruzipain.  
Thiosemicarbazones inhibit Cys proteases through the formation of a reversible tetrahedral 
adduct of the Cys thiolate with the carbon of the thiocarbonyl group (Fig. 8) [134]. However, 
several members of this class of compounds were inactive versus the enzyme, yet were lethal 
to T. cruzi parasites [135-137]. This class of compounds was further modified according to the 
strategy represented in (Fig. 9) [138]. This led to compounds that targeted the parasite but 
were not cruzipain inhibitors. Compound G from (Fig. 4) inhibits cruzipain whereas its 
derivatives, as exemplified by compound in (Fig. 4H), did not. All exhibited strong antiparasitic 
activity. Because of the promiscuity of binding of thiosemicarbazones, this scaffold has been 
deprioritized because of concerns of off-target toxicity. 
Purine Salvage Inhibitors. Allopurinol is an analogue of hypoxanthine that is used to treat 
gout, a condition characterized by deposits of uric acid in bone joints. The mechanism of 
action for this drug involves the inhibition of xanthine oxidase, an enzyme responsible for the 
consecutive conversion of hypoxanthine to xanthine and xanthine to uric acid. T. cruzi is not 
able to perform de novo synthesis of purines and needs to acquire them from the host. Since 
the microorganism does not possess xanthine oxidase, allopurinol is incorrectly sensed as a 
purine substrate and is directly incorporated in the parasite DNA by hypoxanthine-guanine 
phosphoribosyltransferase, disrupting DNA-related processes. Previous assays showed the 
potential of the drug in arresting infection in cultured tissues [139], and a later study with other 
purine and pyrimidine analogues confirmed this activity [140]. In an animal model, allopurinol 
was able to reduce parasite blood levels, but with mild cardiac inflammatory infiltrates at the 
heart. Altogether, the results demonstrated the drug modified the evolution of the infection and 
prevented the acute phase from evolving into chronic cardiac disease [141]. A comparative 
study between itraconazole and allopurinol in preventing chronic Chagas disease in Chile 
showed similar results in preventing cardiomyopathy, but itraconazole was preferred due to 
the fewer adverse effects [142]. A combination of allopurinol with clomipramine, a 
trypanothione reductase inhibitor, to treat Chagas disease in an acute mouse model was 
found to be no better than the use of clomipramine alone [143]. Although there has been an 
interest in the label extension of this drug, early clinical evidence have discouraged the 
development of allopurinol as a drug to treat Chagas [144]. There is an interest in exploiting 
this pathway for Chagas chemotherapy, but to our knowledge no other compounds have been 
recently tested in vivo [145]. Several 4'-substituted and 3',4'-disubstituted 5-benzyl-2,4-
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diaminopyrimidines are selective inhibitors of T. cruzi dihydrofolate reductase and showed 
good in vitro activity against the parasite [146]. 
Inhibitors of Pyrophosphate Metabolism. Another pathway that has gained attention is the 
one responsible for pyrophosphate metabolism. This process does not take place in the 
cytosol but rather at acidocalcisomes, parasite-specific organelles that are also involved in 
calcium hemostasis, response to cell stress, osmoregulation, and energy transduction [147]. It 
has been demonstrated that bisphosphonates, drugs currently used to treat osteoporosis, 
accumulate in the acidocalcisomes and can inhibit a key enzyme of pyrophosphate 
metabolism –farnesyl pyrophosphate synthase [148].  
The first report of this activity in animal models demonstrated that risedronate could reduce 
parasitemia with reductions in mortality, but no complete parasitological cures were achieved 
[149]. In another study, a significant reduction in mortality was observed when CD-1 mice 
were treated with risedronate, but myocardial pathology and ventricular dilatation was 
unchanged in comparison with control. On the other hand, Tulahuen strain infected C57BL/6 
mice had no improvement in mortality [150]. 
More recently, metal complexes of the bioactive, bisphosphonates alendronate [151] 
pamidronate [151] and risendronate [152] were synthetized and showed activity against 
amastigotes, with no toxicity for the mammalian host cells tested. These complexes are 
thought to protect phosphonate groups from ionization at physiological pH, increasing 
bioavailability to target the parasitic farnesyl pyrophosphate synthase [151]. Newly 
synthesized bisphosphonates also proved to be potent inhibitors of T. cruzi farnesyl 
pyrophosphate synthase [153]. 
 
Trypanothione Biosynthesis Inhibitors. Instead of glutathione and glutathione reductase, 
trypanosomatids produce trypanothione and trypanothione reductase for thiol-dependent 
redox metabolism. This is essential in detoxification of free radicals and maintenance of the 
intracellular reducing environment. As this parasite-specific system does not exist in the 
humans, it is considered a potential target [154]. Recently, a study validated the trypanothione 
pathway as drug target by a metabolic modeling approach. All of theconstituent enzymes and 
transporters present are essential for proper pathway function, but not all of them have 
therapeutic potential [155]. Many reductase inhibitors have been identified, including poly-
amine derivatives, crystal violet, acridine-based tricyclics, phenothiazine, benzoazepine, 
isoalloxazine and pyridoquinoline [156-159]. In vivo testing of a trypanothione reductase 
inhibitor, thioridazina, promoted heart protection but failed to completely eradicate the parasite 
[160]. 
Lipid Biosynthesis Inhibitors. Alkyllysophospholipids and lysophospholipid analogues, such 
as miltefosine and edelfosine have been shown to be active against proliferation and 
differentiation of T. cruzi, in vitro and in vivo with good oral activity and low toxicity [161-166]. 
Surprisingly little is known about the role of glycosphingolipids in trypanosomatids. Various 
glycosphingolipids inhibitors have shown antiproliferative activity lysing 79 to 95.5% of 
parasite in an in vitro assay and cytostatic activity in mouse model [167].  
Although T. cruzi glycophosphatidylinositol GPI anchors share the same conserved core as 
othereukaryotes, many often contain a fourth mannose on which resides a galactofuranosyl 
(Galf) linked to the O-3 and an obligatory 2-aminoethylphosphonate (2AEP), also known as 
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ciliatine, linked to O-6 of the glucosamine of all T. cruzi GIPLs and GPI-anchored mucins [168-
170]. 
Enzymes involved in the biosynthesis of the T. cruzi GPI anchors are susceptible to inhibitors 
in different organisms [171, 172]. A recent study identified the orthologous sequences of all 
genes involved in the biosynthesis of the T. cruzi GPIs. Three of these sequences 
complement yeast conditional mutants of these homologues. Unsuccessful attempts to 
generate T. cruzi knockouts for three of these genes further suggested that the GPI is an 
essential component of the organism [173]. 
Although the role of AEP in T. cruzi has not yet been identified, it is a virulence factor in 
pathogens like Bacteroides fragilis [174]. The absence of the AEP biosynthetic enzymes 
(phosphoenolpyruvate mutase, phosphoenolpyruvate decarboxylase & 2-aminoethyl-
phosphonate transaminase) in humans make the pathway a potential candidate for drug 
targeting. Recent investigations by Coron and Smith (unpublished) have genetically validated 
the AEP biosynthetic pathway. They identified compounds with potent in vitro activity against 
the recombinant enzymes of the AEP pathway as well as against T. cruzi epimastigotes. 
CONCLUSION 
Since the discovery of Trypanosoma cruzi as the etiological agent of Chagas disease more 
than 100 years ago, a cure has been pursued. It took 50 years to discover a specific drug, 
nifurtimox, to treat this neglected disease. However, apart from the discovery and 
development of benznidazole some years later, no improvements in chemotherapy have been 
made in safety or effectiveness, despite a half century of intense research. Nevertheless, 
there are reasons to be optimistic. The global nature of the disease and the information about 
its pathology, has brought new researchers to the field. Novel basic and applied research is 
constantly feeding our knowledge of the disease. New partnerships, including with 
pharmaceutical companies, are accelerating efforts traditionally made solely by academia. 
Clinical trials for some candidates have been recently completed, some are under way and a 
few more are planned to begin shortly. But we should not ignore the still long way and 
challenges to find a better treatment for Chagas: resources and funding are scarce, and there 
is a critical need to define beneficial intellectual property agreements and improve data 
sharing for all involved in Chagas disease drug discovery. 
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Figure 1. Current drugs for Chagas disease: (A) benznidazole and (B) nifurtimox. 
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Figure 3. TcCYP51 crystallographic structure (PDB ID: 3KSW). The protein is represented as a gray ribbon, the BC-
region that close the active site and includes residues important of the catalytic activity is colored in red, residues 
surrounding the entrance of the substrate channel are colored in blue. Inside the enzyme, the heme group is colored 
in green with atoms represented as sphere; the binding cavity is occupied by ligands (POZ (PDB ID: 3K1O) and VNF 
(PDB ID: 3KSW)), whose atoms are represented by sphere and colored as follow: purples the moieties that occupy 
the substrate channel; orange the moieties that occupy the deeper binding region; cyan the moieties involved in the 
interaction with the heme group. 
 
 
 
 
Figure 2. Drugs on the pipeline for Chagas disease: (A) posaconazole, (B) E1224, (C) Tak187, (D) K-777, (E) amiodarone. 
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Figure 4. Molecular structure of scaff lds currently being in study for Chagas Disease. 
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Figure 5. Crystallographic structure of cruzipain in complex with a non-peptidic vinylsulfone derivative (PDB-ID: 
3HD3). The protein is represented as a surface colored in gray, specific sites are colored as follow: S1’ in cyan, S1 in 
purple, S2 in yellow, S3 in green. The ligand in represented in stick, colored by atom as follow: C in black, O in red, N 
in blue, S in yellow. 
 
Figure 6. Similarity between chalchones and N-acylhydrazones. 
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Figure 7. Mechanism of inactivation of cruzipain by a tetrafluorophenoxymethyl ketone derivative. 
 
Figure 8. Mechanism of inactivation of Cys proteases by thiosemicarbazones. 
 
Figure 9. Design of hydrazones as anti T. cruzi parasites. 
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